AGAastha Gupta

Aastha Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aastha Gupta has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Ankur Sood

    School of Chemical Sciences and Advanced Materials Research Centre Indian Institute of Technology Mandi Mandi Himachal Pradesh 175075 India

    1 shared publication
  • Dimpy Bhardwaj

    School of Chemical Sciences and Advanced Materials Research Centre Indian Institute of Technology Mandi Mandi Himachal Pradesh 175075 India

    1 shared publication
  • Garima Agrawal

    School of Chemical Sciences and Advanced Materials Research Centre, Indian Institute of Technology Mandi, Mandi, India

    1 shared publication
  • Nishith Shrimali

    Disease Biology Laboratory Regional Centre for Biotechnology National Capital Region Biotech Science Cluster Faridabad Haryana 121001 India

    1 shared publication
  • Prasenjit Guchhait

    Disease Biology Laboratory Regional Centre for Biotechnology National Capital Region Biotech Science Cluster Faridabad Haryana 121001 India

    1 shared publication
  • Ritu Singhmar

    School of Chemical Sciences and Advanced Materials Research Centre Indian Institute of Technology Mandi Mandi Himachal Pradesh 175075 India

    1 shared publication

Latest Publications

  • Functionalized Chitosan Decorated Hafnium Oxide@Gold Core–Shell Nanoparticles for Multimodal Cancer Therapy

    by Aastha Gupta, Ankur Sood, Dimpy Bhardwaj, Nishith Shrimali, Ritu Singhmar, Shubhra Chaturvedi, Prasenjit Guchhait, Garima Agrawal

    Herein, the fabrication of chitosan stabilized multifunctional hafnium oxide@gold core–shell nanoparticles (HAT NPs) (≈12 nm) is described. The developed nanoparticulate system offers multimodal action by providing stimuli responsive anticancer drug delivery along with imparting radiosensitization to cancer cells, thereby protecting surrounding normal tissues from damage. HAT NPs exhibit good capability of loading doxorubicin (DOX), an anticancer drug with ≈87% encapsulation efficiency. DOX loaded HAT NPs are able to release ≈91% DOX under GSH reducing conditions, that is a representative of the cancer cell microenvironment. The cytotoxicity of the developed DOX loaded HAT NPs is tested against breast cancer cells (MDA‐MB‐231) showing higher cytotoxicity as compared to free DOX. In addition, the ability of HAT NPs to generate ROS activity upon irradiation by gamma radiations (0.5 & 5 Gy) is also analyzed in cancer cells to demonstrate the ability of synthesized system as a potent candidate to present radio sensitization. Further, in vivo biodistribution studies are executed to understand the tissue specific retention of HAT NPs for their future utility in targeted cancer treatment applications.